Compare ALLR & MDRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLR | MDRR |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5M | 18.3M |
| IPO Year | 2021 | 2015 |
| Metric | ALLR | MDRR |
|---|---|---|
| Price | $1.22 | $11.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 75.7K | 2.8K |
| Earning Date | 05-15-2026 | 03-02-2026 |
| Dividend Yield | N/A | ★ 2.43% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.74 |
| Revenue | $320,000.00 | ★ $10,396,618.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.74 |
| Revenue Growth | N/A | ★ 6.79 |
| 52 Week Low | $0.77 | $9.47 |
| 52 Week High | $1.88 | $14.52 |
| Indicator | ALLR | MDRR |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 51.51 |
| Support Level | $1.22 | $11.01 |
| Resistance Level | $1.45 | $12.23 |
| Average True Range (ATR) | 0.09 | 0.27 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 14.61 | 44.18 |
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Medalist Diversified Inc owns ten investment properties comprised of three retail properties, three flex/industrial properties, and four STNL properties, including the Tesla Pensacola Property. Through its subsidiary, the company sponsors Delaware Statutory Trusts (DSTs) that provide accredited investors access to institutional-quality real estate with the transparency and governance of a public company. The company has three reportable segments, consisting of retail center properties, flex center properties, and STNL properties. The company generates the majority of its revenue from the Retail Center Property.